Evogene Ltd.EVGNNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank0
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P0
Near historical low
vs 5Y Ago
-5x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -46.13% |
| Q2 2025 | -22.75% |
| Q1 2025 | -6.37% |
| Q4 2024 | -9.30% |
| Q3 2024 | 21.32% |
| Q2 2024 | -38.21% |
| Q1 2024 | -15.40% |
| Q4 2023 | 10.90% |
| Q3 2023 | -6.78% |
| Q2 2023 | 13.54% |
| Q1 2023 | -12.50% |
| Q4 2022 | 9.24% |
| Q3 2022 | -9.43% |
| Q2 2022 | -2.85% |
| Q1 2022 | -17.80% |
| Q4 2021 | 3.26% |
| Q3 2021 | 16.85% |
| Q2 2021 | 16.03% |
| Q1 2021 | -10.68% |
| Q4 2020 | 20.34% |
| Q3 2020 | 9.29% |
| Q2 2020 | -15.99% |
| Q1 2020 | -3.14% |
| Q4 2019 | 24.76% |
| Q3 2019 | 3.53% |
| Q2 2019 | -1.81% |
| Q1 2019 | -8.14% |
| Q4 2018 | 11.90% |
| Q3 2018 | 13.95% |
| Q2 2018 | -1.07% |
| Q1 2018 | -39.91% |
| Q4 2017 | 7.29% |
| Q3 2017 | 8.21% |
| Q2 2017 | -1.59% |
| Q1 2017 | -14.43% |
| Q4 2016 | 19.95% |
| Q3 2016 | -2.86% |
| Q2 2016 | 9.32% |
| Q1 2016 | -10.80% |
| Q4 2015 | 27.17% |